1. Academic Validation
  2. Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling

Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling

  • Oncotarget. 2017 Oct 19;8(60):101965-101983. doi: 10.18632/oncotarget.21949.
Xu-Wei Zhou  # 1 Yuan-Zheng Xia  # 1 Ya-Long Zhang 1 Jian-Guang Luo 1 Chao Han 1 Hao Zhang 1 Chao Zhang 1 Lei Yang 1 Ling-Yi Kong 1
Affiliations

Affiliation

  • 1 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • # Contributed equally.
Abstract

In this study, we investigated the mechanism by which tomentodione M (TTM), a novel natural syncarpic acid-conjugated monoterpene, reversed multi-drug resistance (MDR) in Cancer cells. TTM increased the cytotoxicity of chemotherapeutic drugs such as docetaxel and doxorubicin in MCF-7/MDR and K562/MDR cells in a dose- and time-dependent manner. TTM reduced colony formation and enhanced Apoptosis in docetaxel-treated MCF-7/MDR and K562/MDR cells, and it enhanced intracellular accumulation of doxorubicin and rhodamine 123 in MDR Cancer cells by reducing drug efflux mediated by P-gp. TTM decreased expression of both P-gp mRNA and protein by inhibiting p38 MAPK signaling. Similarly, the p38 MAPK Inhibitor SB203580 reversed MDR in Cancer cells by decreasing P-gp expression. Conversely, p38 MAPK-overexpressing MCF-7 and K562 cells showed higher P-gp expression than controls. These observations indicate that TTM reverses MDR in Cancer cells by decreasing P-gp expression via p38 MAPK inhibition.

Keywords

P-glycoprotein; meroterpenoid; multidrug resistance; p38; tomentodione M.

Figures
Products